ELAB (Elevai Labs Inc.) Utang jangka cendhak marang modal

Elevai Labs Inc. (ELAB) price action on the GURU.Markets platform demonstrates the 0.63 indicator. Elevai Labs Inc. (ELAB) generates revenue from premium exosome-based rejuvenation, which grants the company significant pricing power. The business relies on expanding B2B serum sales to aesthetic clinics to capture market share, while production capacities are currently being modernized and automated to increase the output of new product lines.

This ratio is calculated as the proportion of liabilities with a maturity of up to one year to equity, allowing for an assessment of short-term financial stability and the business's reliance on debt financing. For Elevai Labs Inc. (ELAB), which is developing the exosome market in aesthetic medicine, analyzing the short-term debt-to-capitalization chart is critical when evaluating the balance between R&D investments and liquidity.